NIKKEI 225
38,385.73 +29.67 (+0.08%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.83 +0.81 (+1.04%) GOLD FUTURES
2,392.80 +32.90 (+1.39%) DOW
39,848.31 +290.20 (+0.73%) Bitcoin GBP
52,055.75 +3,548.29 (+7.31%)
REGN Jan 2026 1060.000 call
| Previous close | 130.47 |
| Open | 129.70 |
| Bid | 123.00 |
| Ask | 133.00 |
| Strike | 1,060.00 |
| Expiry date | 2026-01-16 |
| Day's range | 129.70 - 130.47 |
| Contract range | N/A |
| Volume | |
| Open interest | 21 |
ZacksSanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag
Sanofi (SNY) and Regeneron's (REGN) Dupixent is poised to be the first medicine for adolescents with inadequately controlled CRSwNP, if approved by the FDA.
GlobeNewswireDupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately controlled CRSwNP, a condition driven in part by underlying type 2 inflammation that obstructs the sinuses and nasal passages and can lead to a loss of sense of smell Current treatment options for adolescents with CRSwNP leave many patients with uncontrolled disease and often result in the recurrence of nasal polyps TARRYTOWN, N.Y. and PARIS, May 13, 2024 (GLOBE NEWSWIRE) -
Simply Wall St.Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) large institutional owners must be happy as stock continues to impress, up 3.2% over the past week
Key Insights Institutions' substantial holdings in Regeneron Pharmaceuticals implies that they have significant...
